Psoriasis response to brodalumab: dose response and time course
Summary:
Analysis of non-lesional and lesional psoriatic skins for up to 43 days following treatment with various doses of brodalumab, a human IgG2 mAb that selectively binds and blocks signaling through IL-17RA. Results provide insight into the molecular effect of blocking IL-17 signaling in psoriatic skin.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Russell CB, Rand H, Bigler J, Kerkof K et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol 2014 Apr 15;192(8):3828-36. PMID: 24646743
